Hemispherx say they intend to do a proper Phase III.
From the last conference call in October: They have done a retrospective on their AMP516 phase III data with help from WPI and they have identified an XMRV+ sub-group. See slide 13 here:
http://www.wsw.com/webcast/rrshq18/heb/
They said they intend on meeting with the FDA next January or February - much of the delay has been due to PCR and blood culture testing of the 516 and waiting for the XMRV controversy to sort itself out. I think the Lo/Alter study satisfied them as far as xmrv is concerned. It is my opinion, and my opinion only, that these
new trial centers will offer the new Phase III trial once it is approved by the FDA. It only makes sense. But they cannot say anything about a 516 type trial until the FDA approves it.
Hemispherx is conducting a conference call next Tuesday:
http://finance.yahoo.com/news/Hemispherx-Biopharma-Inc-to-pz-673267569.html?x=0&.v=1 to discuss recent developments. They may have more recent information on the new Phase III trial. If anyone is interested in their ampligen trials, you should follow their SEC filings and their conference calls.